Astena Holdings Co.,Ltd. AI Stock Analysis
Want to see JP:8095 full AI Analyst Report?
Astena Holdings Co.,Ltd. (8095) AI Stock Analysis
Astena Holdings Co.,Ltd.
(TSE/TYO:8095)
The stock's attractive valuation and solid technical uptrend are the primary strengths. However, these are tempered by a moderate financial profile characterized by weak free cash flow and increasing leverage, which introduces risk.
Astena Holdings Co.,Ltd. (8095) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 22.32B
- Dividend Yield
- 3.26%
- Average Volume (3M)
- 164.19K
- Price to Earnings (P/E)
- 8.7
- Beta (1Y)
- 0.61
- Revenue Growth
- 13.23%
- EPS Growth
- ―
- Country
- Japan
- Employees
- 1,543
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Medical - Pharmaceuticals
Astena Holdings Co.,Ltd. Business Overview & Revenue Model
Company Description
Astena Holdings Co., Ltd., a Japanese company founded in 1914 and based in Chuo, is engaged in the development and distribution of a wide array of healthcare and chemical products. Its Fine Chemical division specializes in manufacturing and selling a...
How the Company Makes Money
Astena Holdings makes money primarily through its consolidated subsidiaries’ business activities, with revenue largely generated from the sale and distribution of products handled by the group. Key revenue streams typically include (1) wholesale/dist...
Astena Holdings Co.,Ltd. Financial Statement Overview
Summary
Financial performance is mixed. Revenue growth and gross margin expansion are positive, but net margins remain low and volatile. The balance sheet shows rising leverage, and free cash flow generation is weak relative to net income, indicating ongoing capital intensity.
Income Statement
65PositiveBalance Sheet
55NeutralCash Flow
50Neutral| Breakdown | TTM | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 62.74B | 62.74B | 57.99B | 51.98B | 49.64B | 72.32B |
| Gross Profit | 21.87B | 21.87B | 19.37B | 16.32B | 15.44B | 16.60B |
| EBITDA | 5.55B | 5.51B | 849.75M | 4.17B | 3.60B | 4.97B |
| Net Income | 2.19B | 2.19B | -2.53B | 1.16B | 579.60M | 1.74B |
Balance Sheet | ||||||
| Total Assets | 75.44B | 75.44B | 64.60B | 67.25B | 63.55B | 63.55B |
| Cash, Cash Equivalents and Short-Term Investments | 10.19B | 10.19B | 6.10B | 6.88B | 6.93B | 10.93B |
| Total Debt | 22.65B | 22.65B | 14.99B | 16.99B | 15.05B | 15.16B |
| Total Liabilities | 48.04B | 48.04B | 39.29B | 38.65B | 36.48B | 36.55B |
| Stockholders Equity | 27.08B | 27.08B | 25.17B | 28.42B | 26.99B | 27.00B |
Cash Flow | ||||||
| Free Cash Flow | 500.00M | 500.00M | 1.65B | -2.52B | -3.77B | -2.14B |
| Operating Cash Flow | 3.39B | 3.39B | 4.85B | 1.64B | -742.42M | 1.35B |
| Investing Cash Flow | -5.55B | -5.55B | -2.94B | -2.83B | -2.22B | -4.38B |
| Financing Cash Flow | 6.19B | 6.19B | -2.65B | 1.08B | -1.09B | 6.35B |
Astena Holdings Co.,Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:8095, the sentiment is Positive. The current price of 552.00 is above the 20-day moving average (MA) of 538.35, above the 50-day MA of 533.94, and above the 200-day MA of 501.27, indicating a bullish trend. The MACD of 5.31 indicates Negative momentum. The RSI at 57.17 is Neutral, neither overbought nor oversold. The STOCH value of 52.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:8095.
Astena Holdings Co.,Ltd. Peers Comparison
Overall Rating
- JP:809562Neutral
JP:435060Neutral
JP:489055Neutral
JP:341752Neutral
JP:279643Neutral
JP:190A32Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 63Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
| JP:8095 | 62Neutral | JPY 22.44B | 8.71 | ― | 3.26% | 13.23% | ― |
| JP:4350 | 60Neutral | JPY 15.57B | 17.57 | ― | 2.30% | 6.89% | -55.21% |
| JP:4890 | 55Neutral | JPY 5.79B | -7.74 | ― | ― | -39.46% | -317.84% |
| JP:3417 | 52Neutral | JPY 13.96B | 18.12 | ― | 3.02% | 2.87% | -73.55% |
| JP:2796 | 43Neutral | JPY 5.96B | 59.72 | ― | 2.76% | 7.64% | ― |
| JP:190A | 32Underperform | JPY 3.54B | -2.33 | ― | ― | ― | 24.21% |
* Industrials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:8095 | Astena Holdings Co.,Ltd. | 552.00 | 96.48 | 21.18% | |
| JP:2796 | Pharmarise Holdings Corp. | 507.00 | -18.84 | -3.58% | |
| JP:3417 | Ohki Health Care Holdings, Inc. | 995.00 | -402.29 | -28.79% | |
| JP:4350 | Medical System Network Co., Ltd. | 522.00 | 37.09 | 7.65% | |
| JP:4890 | Tsubota Laboratory Incorporated | 217.00 | -127.00 | -36.92% | |
| JP:190A | Chordia Therapeutics Inc. | 46.00 | -61.00 | -57.01% |
Astena Holdings Co.,Ltd. Corporate Events
Astena Holdings Tightens Shareholder Benefit Rules to Reward Long-Term Investors
Astena Holdings Co., Ltd. will revise how it determines categories under its shareholder benefit program, shifting from a single annual reference date to a system that evaluates shareholdings on both May 31 and November 30. The change is intended to...
Astena Holdings Expands PWB Equipment Production With New China Subsidiary
Astena Holdings’ subsidiary Tokyo Kakoki plans to establish Tokyo Kakoki (Zhejiang) Co., Ltd. in Jiaxing, Zhejiang, as a wholly owned second-tier subsidiary to design, manufacture, and sell PWB and flat panel surface treatment equipment. With capital...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026